Pharmicell Co., Ltd. (KRX:005690)
South Korea · Delayed Price · Currency is KRW 18,290
+90 (0.49%)
At close: Nov 4, 2025
Pharmicell Revenue
Pharmicell had revenue of 3.65B KRW in the quarter ending June 30, 2014, a decrease of -58.16%. This brings the company's revenue in the last twelve months to 23.94B, down -3.60% year-over-year. In the year 2013, Pharmicell had annual revenue of 33.41B with 200.63% growth.
Revenue (ttm)
23.94B
Revenue Growth
-3.60%
P/S Ratio
45.83
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.10T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2013 | 33.41B | 22.29B | 200.63% |
| Dec 31, 2012 | 11.11B | 829.38M | 8.07% |
| Dec 31, 2011 | 10.28B | 3.07B | 42.47% |
| Dec 31, 2010 | 7.22B | 28.94M | 0.40% |
| Dec 31, 2009 | 7.19B | -1.14B | -13.68% |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |